Investment Pitches

Pitch Summary:
The pitch highlights a potential sum-of-the-parts opportunity at $CAU.L (Centaur Media), a small-cap conglomerate trading at ~5x LTM EBIT and currently undergoing a strategic review following the resignation of its CEO and the appointment of the chairman as interim CEO. The situation is framed as potentially analogous to Carr's Group, where asset divestments followed leadership changes involving the same individual. Strategic optionality is reinforced by the presence of Harwood Capital as CAU’s largest shareholder with a ~30% stake. The crown jewel is a dominant UK legal journal business serving professional lawyers, characterized by high margins, stable growth, and niche market leadership, which alone could be worth more than CAU’s current enterprise value. The remainder of the portfolio—primarily an online mini-MBA and other lower-margin assets—accounts for the majority of revenue but has weaker economics and declining profitability. The author questions whether a full liquidation (and elimination of corporate costs) is realistic, noting that recent management commentary emphasized strategic planning rather than divestments, but argues that valuation provides sufficient margin of safety to wait for clarity.

BSD Analysis:
Centaur’s equity is effectively a bet on whether governance change catalyzes value realization or leaves a structurally discounted conglomerate intact. The legal information business appears to possess genuine moat characteristics—pricing power, high renewal rates, and minimal competitive intensity—supporting a valuation that could eclipse the group’s current EV. Industry structure is less forgiving for the remaining education assets, where competition is intense, growth has normalized post-COVID, and corporate overhead meaningfully dilutes standalone value. The strategic review creates optionality, but the absence of explicit divestment signals suggests execution risk around unlocking SOTP value. Activist influence increases the probability of action, though partial divestments may fail to eliminate central costs and thus limit upside. Valuation at ~5x EBIT offers downside protection assuming the core legal asset remains stable. Upside hinges on decisive capital allocation—either asset sales or full liquidation—rather than organic turnaround in structurally weaker segments.

Actual Post Content:
An intersting SOTP setup unfolding over at $CAU.L CAU is a small-cap conglomerate trading at 5x LTM EBIT, currently exploring strategic alternatives following the resignation of its CEO and the appointment of the chairman as the new CEO. The same guy was previously appointed to the board of $CARR.L, which began divesting assets shortly afterward. This is particularly relevant because CARR.L is also an investment of Harwood Capital, the largest shareholder of CAU.L with a 30% stake. There is a good chance we may see some assets divested here—or perhaps even a full liquidation. CAU has a portfolio of journals and an educational platform (an online mini-MBA). One of its businesses is a dominant, UK-focused legal journal catering exclusively to professional lawyers. This segment is the crown jewel, boasting exceptionally high margins, stable growth, and clear market leadership in its niche. The legal business alone could be worth more than the entire EV of the company today, leaving multiple other businesses—comprising more than 70% of revenue—essentially for free (lower margin businesses though). My key concern is whether the liquidation is really in the cards here. Beyond the legal segment, the most of the remaining value comes from the mini-MBA segment—a highly competitive market. One could argue that its growth (now down year-over-year by almost 40% on ebitda basis) was largely propped up during COVID. More importantly, once you factor in corporate costs—which are quite significant here—there isn’t much value left in these remaining segments. For this to truly work, you would have to argue for a full liquidation, meaning the complete elimination of corporate costs. However, I’m not convinced that’s what will happen. In the latest update, the new CEO primarily discussed strategic planning rather than hinting at any divestment plans. So, we may not even see a partial divestment, let alone a full liquidation. However, the company is cheap enough as it is, so assuming the other parts of the business don’t fall apart, there is a decent margin of safety to wait and see how the strategic review will be resolved. @adriantford has an interesting piece on this name if you’re intrigued.

URL: https://x.com/InvestSpecial/status/1887069394171297806

Pitch Summary:
MGP Ingredients is facing significant challenges in the American whiskey industry, with sales volumes declining. The company's stock is trading at high multiples relative to its replacement cost, suggesting overvaluation. A potential re-rating to its tangible book value could imply a substantial downside.

BSD Analysis:
MGP Ingredients is currently trading at an enterprise value of $1 billion, significantly above its tangible book value of $0.3 billion. This discrepancy suggests that the market may be overvaluing the company's assets, especially given the ongoing challenges in the whiskey industry. The American whiskey market has seen a 4% decline in sales volumes through the first three quarters of 2024, marking the largest drop in a decade. If MGP's valuation were to align more closely with its tangible book value, it could result in a 70% downside from current levels. Investors should closely monitor the company's upcoming FY24 results for insights into its operational performance and management's outlook on the industry. The potential for a re-rating closer to its tangible book value presents a compelling short opportunity.

Pitch Summary:
The pitch argues that $ASPI (ASP Isotopes) is materially undervalued based on sum-of-the-parts logic, with the market effectively assigning zero value to several high-potential segments. By 2026, the medical isotopes business alone is projected to reach ~$95m ARR with ~$80m in gross profit, and assuming quarterly operating costs of $8–9m, roughly ~$45m of EBITDA—implying ~9x 2026 EV/EBITDA on today’s valuation. The author highlights PET labs as an underappreciated asset, emphasizing the benefits of vertical integration between isotope production and processing into hospital-ready radioisotopes. In nuclear, ASPI is expected to begin HALEU production in 2026 in partnership with NECSA, with TerraPower cited as the first customer and management expecting first-mover status in Western supply. By 2027, metric-ton-scale HALEU output could generate ~$10m of gross profit per ton, yet this business is being spun off into Quantum Leap Energy (QLE) and implicitly valued at zero. The pitch also points to upside in Si-28 for semiconductors, with contracts in place, high purity pricing, and meaningful scalability already built.

BSD Analysis:
ASPI represents a rare case of deep-tech vertical integration across medical isotopes, nuclear fuel, and semiconductor materials, each benefiting from structural supply constraints and high barriers to entry. The medical isotope segment offers near-term cash flow and valuation support, while PET lab integration improves margin capture and defensibility versus pure producers. HALEU is the most asymmetric driver: Western supply scarcity, regulatory complexity, and technical difficulty create a powerful moat for early entrants, and even modest production volumes can support substantial enterprise value. The planned QLE spin-off could act as a catalyst by forcing market recognition and attracting thematic uranium capital flows. Si-28 adds longer-dated optionality tied to advanced semiconductor demand, with early commercial validation already in place. Key risks include execution across multiple capital-intensive programs and regulatory timelines, but the current valuation implies failure across all non-medical segments simultaneously. If even one of nuclear or semiconductors scales as outlined, today’s enterprise value appears to underwrite an overly pessimistic outcome.

Actual Post Content:
Adding it al up for 2026 - just on the medical isotopes - we'll be at $95mm ARR, with gross profits of 80mm. Assume quarterly costs rise to 8-9mm per quarter and you got about 45mm ebitda. That makes today's value around 9 times ’26 ev/ebitda. This implies 0 on SI-28, 0 from One quick note on PET-labs, as it is under-appreciated by investors. PET labs processes isotopes into ready-to-use radioisotopes for hospitals ASPI + PET-labs is a nifty combination, the benefits of vertical integration are subtantial. PET-labs, is aiming to expand beyond Now, let's talk #nuclear. In 2026, ASPI is expected to start HALEU production (fuel for SMRs) in partnership with NECSA (at the Pelindaba facility). TerraPower is known to be its first client, and its CEO seems to think ASPI will be the first to market. $ASPI believes by 2027 they'll able to produce metric ton quantities. A metric ton HALEU costs $20mm, and adds 10mm in gross profits. Multiply the production output for your own estimates. As can be read in the screenshot above, ASPI is spinning off its nuclear business (Quantum Leap Energy) in 2025. $ASPI shareholders will receive QLE shares. #Uranium ETFs (URA, URNM, VanEck) will likely add QLE (as it's a pure-play uranium company) to their uranium baskets. So let's get this straight. ASPI/QLE is the first-to-market, Western provider of HALEU, has a strong moat (I hear uranium enrichment is kinda tricky), and likely the lowest-cost provider in a high-growth market, and we have it valued at 0? To me, that sounds insane. This segment alone could be worth hundreds of millions. Now onto #semiconductors and Si-28. There are contracts in place with a top-5 #semiconductor leader + major industrial gas company. ±5kg contracted in 2025 → 10x scalability (50kg/yr capacity ready) Currently priced at $550k/kg, at 99.995% purity.

URL: https://x.com/shjverborg/status/1886822796187128167

Pitch Summary:
Misrepresented its product specification; no chance of getting much sales; no shipping of any sample contrary to its claims; not a single disclosed customer for its flagship product; not a qualified vendor at Amazon;

BSD Analysis:
Applied Optoelectronics provides optical transceivers, primarily for data centers and cable operators. Bears argue that customer concentration, cyclical demand, and low margins make it vulnerable. While AI-driven data center growth could provide tailwinds, execution has historically been inconsistent. With reliance on a handful of hyperscale customers, any order cuts could drive sharp earnings downgrades.

Pitch Summary:
Natural Resource Partners (NRP) presents a compelling investment opportunity due to its robust royalty business model, which ensures high free cash flow margins and resilience against coal price volatility. The company benefits from a low-cost structure, as lessees handle all mining expenses, allowing NRP to maintain profitability across various market conditions. The investment thesis is anchored on debt reduction and increased distributions, which are expected to enhance shareholder value significantly. Despite the coal industry's negative perception, NRP's strategic positioning and management's focus on value creation make it an attractive investment.

BSD Analysis:
NRP's valuation appears attractive, trading at 4-6x normalized free cash flow, largely due to its association with the coal industry and its MLP tax structure. The company's focus on debt reduction has been effective, with significant progress made since 2016 when it faced financial distress. Management's ownership of 30% aligns their interests with shareholders, further supporting the investment case. Additionally, NRP's 49% stake in Sisecam Wyoming offers potential upside from the soda ash market, while its extensive land holdings provide optionality for future carbon capture initiatives. These factors, combined with a disciplined capital allocation strategy, position NRP for substantial returns, even without factoring in potential contributions from soda ash or carbon capture projects.

Pitch Summary:
Thryv Holdings presents a compelling investment opportunity due to its ongoing transformation from a declining Yellow Pages business to a high-growth SaaS company. The market has yet to fully recognize the value of Thryv's SaaS segment, which is experiencing rapid growth and offers recurring, non-discretionary revenue streams. As the company completes its transition to a primarily software-focused business, a significant stock price re-rating is anticipated, with potential for substantial upside.

BSD Analysis:
Thryv's SaaS segment is valued at 12.9x 2025E EBITDA and 2.2x 2025E revenue, which is considered undemanding given its growth trajectory and high margins. The company has consistently achieved 20%+ revenue growth, supported by a capital-light model with over 70% gross margins. Comparatively, peers like HUBS and TTAN trade at significantly higher revenue multiples, suggesting room for valuation expansion. Thryv's management has a strong track record, having met or exceeded guidance since the IPO. The company's strategy to convert legacy Yellow Pages customers and expand its client base in a large addressable market positions it well for continued growth. Despite potential risks such as economic downturns affecting SMB clients, Thryv's focus on recession-resilient industries and management's significant ownership stake mitigate concerns. As Thryv transitions to a pure-play SaaS company, it is likely to attract more attention from software-focused investors, potentially catalyzing a re-rating of its stock.

Pitch Summary:
The pitch revisits the author’s successful prior trade in $HIMS (Hims & Hers Health) and introduces a new, explicitly speculative position in $LFMD (LifeMD). LifeMD is framed as structurally different from HIMS, emphasizing a clinician-led model where patients meet with doctors rather than self-selecting prescriptions, potentially resulting in a stickier, higher-quality customer base. The company has also vertically integrated into pharmacy fulfillment, which could improve economics over time. While GLP-1 sales are expected to roll off later in the year, LifeMD is near breakeven and currently spends ~$26m per quarter on advertising; stripping out marketing implies ~$70m of income on a ~$244m market cap. The author argues this adjustment is reasonable if customer payback periods are attractive and marketing represents an investment in future cash flows rather than a recurring necessity. Additional optionality comes from a non-core PDF signing asset (WorkSimpli) and ~25% insider ownership. The position is small, opportunistic, and acknowledged as lower conviction, with entry around $5.50.

BSD Analysis:
LifeMD occupies a different point on the telehealth spectrum, prioritizing medical engagement and compliance over pure convenience, which may support better retention and lifetime value than transactional prescription models. Industry structure remains challenging, with customer acquisition costs elevated and regulatory scrutiny rising, but vertical integration into pharmacy could improve unit economics if scale is achieved. Adjusting out marketing is aggressive, yet directionally useful in assessing whether the underlying service model can generate contribution profit once growth spending moderates. The removal of GLP-1s creates a near-term earnings air pocket but also forces clarity on core demand sustainability. Insider ownership aligns incentives, though balance-sheet and cash flow discipline will matter as advertising efficiency is tested. Valuation implies skepticism that normalized earnings can emerge without heavy spend, leaving upside if payback assumptions prove conservative. This is a high-variance, execution-dependent setup where modest operational progress could drive meaningful re-rating, but downside remains if growth proves inseparable from marketing intensity.

Actual Post Content:
Feels like a while ago I pitched you guys $HIMS at $5.98, ironically was my largest position but I sold almost all of it around $10-$14. Very speculative idea here, definitely not a high conviction trade, but I purchased a small position in LifeMD. $LFMD LifeMD is an entirely different model from HIMS, unlike HIMS being a pill shop where you fill out the equivalent of a Google Form and ask for what you want, LifeMD makes you actually meet with a doctor. Seems like a classifier model, and in recent months they have also established their own affiliated pharmacy to server their customers. My 'accounting' for the $HIMS idea was contentious, but LifeMD is close to breakeven profitability and spending $26 Million a quarter on advertising. Obviously the elimination of selling GLP1s later this year will dink earnings a bit, but if you strip out marketing expense, the company is trading at $244 Million market cap and $70 Million in income after adjusting marketing out. The reason I think it is mildly acceptable to strip out marketing expense is for these types of names, especially LifeMD which likely has a stickier customer base since people actually meet a doctor, the market expense is really just a trade. You are buying now, in exchange for future cash flows from the customers, if the payback period is 24 months it makes sense. They also have a pdf signing application called work simpli which I think could be sold and the insider ownership of 25% is acceptable to me. Very speculative position, not a high conviction trade, but I bought a few thousand around 5.50. Probably a much better entry at $4, but I felt like buying it.

URL: https://x.com/blondesnmoney/status/1886486969489711365

Pitch Summary:
Zegona Communications has demonstrated significant operational improvements following its acquisition of Vodafone Spain, with increased profitability and efficiency. The company's strategy involves monetizing its fiberco assets at premium multiples to deleverage and potentially fund a substantial special dividend. Recent developments, including the finalization of the MasOrange fiberco deal and bids for the Telefonica fiberco, support the thesis of unlocking significant equity value.

BSD Analysis:
Zegona's acquisition of Vodafone Spain has already shown promising results, with EBITDA improvements and a strategic focus on monetizing fiberco assets. The company's leverage structure amplifies the potential equity value gains from these operational efficiencies. The telecom industry is expected to see pricing increases, further supporting revenue growth. Additionally, the high multiples anticipated for fiberco asset sales could provide substantial proceeds for debt reduction and shareholder returns. However, investors should be mindful of the complex capital structure and the potential for execution risks in realizing these asset sales and operational improvements.

Pitch Summary:
MKSI is our early play in the emerging quantum computing space. The company provides the ‘plumbing’ for quantum computing, i.e., critical technology and parts needed to build and advance the technology. MKSI also has a core business in the semiconductor space with enterprise customers like Samsung, SK Hynix, Taiwan Semiconductor Manufacturing, ASML, and others. Earnings are also strong—in the fiscal year ending Q3 2023, MKSI saw a 58% increase in net income and 17.81% year-over-year earnings growth. We forecast a steady 8%+ annual growth in the top-line through 2026, which with margin expansion can increase EPS at least 20% per year.

BSD Analysis:
MKS Instruments enters 2026 as a premier beneficiary of the wafer fab equipment (WFE) super-cycle, driven by the global build-out of AI infrastructure. The company is forecast to achieve an annual earnings growth rate of nearly 52% through 2027, significantly outperforming its industry peers. Management has outlined a strong 2026 outlook supported by top-line growth and cost structure optimization following the successful integration of Atotech. Key growth drivers for 2026 include the company's leading position in RF power and photonics technology, which are critical for the advanced etching and lithography required to produce next-generation AI chips. MKS is currently present in 85% of global semiconductor manufacturing equipment, positioning it as an essential "all-weather" supplier. Analysts have recently raised price targets toward the $215 range, citing the company's aggressive deleveraging goals and its unique exposure to advanced packaging and multi-layered substrates for AI servers.

Pitch Summary:
We purchased SNOW anticipating strong earnings, which in December exceeded street estimates. The stock has rallied since our initial positioning. We’re forecasting strong earnings and revenue growth in the new year as Snowflake’s customer base has expanded considerably. We think SNOW’s sizable investments in AI solutions within its product suite will accelerate profitability growth.

BSD Analysis:
Snowflake has redefined its 2026 narrative through a landmark pivot toward AI-native infrastructure. The company enters the final quarter of its fiscal 2026 (ending Jan 31, 2026) with a product revenue guidance of $4.45 billion, representing roughly 28% year-over-year growth. Management is targeting a non-GAAP product gross margin of 75% and an adjusted free cash flow margin of 25% for the full year. A primary catalyst for 2026 is the rapid monetization of Snowflake Cortex AI, which allows enterprise customers to run advanced large language models (LLMs) natively on their data. Strategic partnerships, including a multi-year deal with OpenAI, are expected to drive higher compute consumption as customers move AI projects from pilot to production. Despite some concerns over slower billings, institutional confidence remains bolstered by a net revenue retention rate of 125% and a growing base of $1 million-plus customers.

Pitch Summary:
Boeing has installed a new CEO in Kelly Ortberg, whose office in Seattle will be as close to the commercial production lines as possible—which is also 2,300 miles from the company’s corporate offices in Arlington, VA. Ortberg will be on the factory floor in Renton, Washington, where Boeing makes its 737 MAX planes. We see this as a commitment to retool the company culture and put the focus back on Boeing as an aerospace leader and pioneer. Boeing’s share price has been battered since the 737 MAX was first grounded in 2019, and we see potential for a turnaround under Ortberg’s leadership.

BSD Analysis:
Boeing enters 2026 at a historic pivot point, with the market increasingly viewing this as the definitive "turnaround year" following years of production and regulatory setbacks. The company officially received FAA approval to ramp up 737 MAX production, aiming to reach a rate of 50+ aircraft per month by mid-2026, while concurrently targeting a production rate of 10 aircraft per month for the 787 Dreamliner. Management has projected low single-digit billions in positive free cash flow for 2026, which would mark the first sustainably positive cash flow year since the pre-MAX crisis era. The certification of the 737 MAX 7 and MAX 10 variants remains the primary product catalyst for the year, alongside a record order backlog that now exceeds $636 billion. While the stock has rallied to a two-year high near $248, analysts maintain a "Moderate Buy" consensus with a median price target of $258, noting that high leverage and continued FAA scrutiny remain the primary risks for the fiscal year.

Pitch Summary:
Curiosity Stream is undervalued due to its significant cost-cutting and restructuring efforts, which have led to profitable growth. The company has announced AI dataset licensing deals that are expected to nearly double next twelve months (NTM) earnings. Despite this, the market prices the company as if it is on the verge of liquidation. As the market adjusts to the company's earnings inflection, shares could trade closer to 8x cash flow, presenting a 123% upside.

BSD Analysis:
Curiosity Stream has undergone significant restructuring to focus on profitability, including reducing overhead and increasing subscription prices. The company is poised to benefit from AI licensing deals, which are expected to significantly boost revenue. Despite a challenging competitive landscape, Curiosity Stream has carved out a niche in the documentary streaming space. The company is also expanding into free ad-supported streaming television (FAST), which could provide additional revenue streams. With a strong cash position and potential acquisition interest, Curiosity Stream is well-positioned for future growth. The company's management, with significant industry experience, is focused on leveraging these opportunities to drive shareholder value.

Pitch Summary:
The pitch argues that $SKYE (Skye Bioscience) is a standout junior biotech opportunity heading into 2025, driven by a differentiated obesity program and a strong balance sheet. Skye holds ~$76.5m in cash versus an ~$88m market cap, providing runway into mid-2027 ahead of key clinical catalysts. Its lead asset, nimacimab, is a CB1 inhibitor (explicitly not a GLP-1) that has demonstrated meaningful weight loss in preclinical models (~16% in mice) with an unusually favorable tolerability profile. Unlike prior CB1 approaches, nimacimab does not act directly on the brain, and to date has shown zero neuropsychiatric adverse events and minimal GI side effects (<5%), a stark contrast to GLP-1s and small-molecule competitors. The drug’s mechanism reduces fat storage and increases energy expenditure, with early evidence suggesting no muscle loss—potentially addressing a major drawback of GLP-1 therapies. Nimacimab could be positioned as either a standalone therapy or a complementary agent alongside GLP-1s. Human Phase 2 data expected in June/July 2025 is framed as the key inflection point.

BSD Analysis:
Skye’s appeal lies in targeting obesity through a mechanistically orthogonal pathway at a time when tolerability, durability, and body composition are emerging as the next competitive frontiers beyond pure weight loss. Industry structure suggests room for combination regimens and non-GLP-1 modalities, particularly if they mitigate muscle loss or GI burden that limit long-term adherence. The CB1 class carries historical baggage, but nimacimab’s peripheral activity and clean safety profile, if sustained in humans, could materially re-rate the risk profile. Valuation currently reflects little probability-adjusted success despite ample cash and a near-term Phase 2 catalyst. The primary risk is translational—animal efficacy and tolerability must hold up clinically to justify differentiation versus an increasingly crowded obesity pipeline. However, even mid-tier efficacy with superior safety could support meaningful strategic value as either a partnerable adjunct or standalone niche therapy. The setup is asymmetric: balance-sheet protection limits downside into data, while credible human proof-of-concept could unlock a step-change in perceived earnings power.

Actual Post Content:
Sent this out to subscribers on the open yesterday--$SKYE WHY SKYE BIOSCIENCES (SKYE-NASD) IS ONE OF THE TOP JUNIOR BIOTECH STOCKS TO WATCH IN 2025: ⭐️ $76.5M CASH as of SEPT 30 24 VS $88 M MARKET CAP (30.338 M x $2.78/sh)—CURRENT CASH GIVES RUNWAY TO MID 2027 ⭐️CB1 inhibitors (NOT GLP1!!!!) shows EFFECTIVE WEIGHT LOSS in humans ⭐️SKYE’S CB1 molecule, called NIMACIMAB, SHOWS 16% weight loss in ANIMAL TESTING – MICE (see graphy below) ⭐️HUMAN PHASE 2 DATA DUE JUNE/JULY 2025 ⭐️NIMACIMAB ALSO SHOWS MUCH GREATER TOLERABILITY a) ZERO NEURO-PSYCHIATRIC ADVERSE EVENTS THUS FAR! b)LESS THAN 5% OF PATIENTS REPORT GI ISSUES GI issues are HUGE for all others and be NIMACIMAB’S #1 BENEFIT---small molecule competitors = 30% GI issues & WEGOVY & ZEPBOUND =70%++ ⭐️SKYE’S NIMACIMAB does not act directly on the brain ⭐️It reduces energy storage in the form of fat and increases energy expenditure even while you are still ⭐️NIMACIMAB COULD BE STANDALONE OR COMPLEMENT TO CURRENT GLP-1 TREATMENT ⭐️40% of GLP-1 weight loss is muscle. CB1 research so far shows NO MUSCLE LOSS—DRAMATIC. IF NIMACIMAB SHOWS WEIGHT LOSS ON PAR WITH OTHER CB1 MOLECULES...etc

URL: https://x.com/oilandgasinvest/status/1885002126696608109

Pitch Summary:
The pitch focuses on a sharp selloff in $9552.T (M&A Research Institute), which is trading limit down following weak Q1 earnings driven by margin compression. Revenue growth slowed as deal closures lagged, while hiring was front-loaded, resulting in a ~50% decline in operating profit. Despite record deals in progress (1,352, +11.2% QoQ), only 728 deals closed, with fees per deal declining materially, creating a temporary mismatch between cost growth and revenue realization. The company hired 43 employees in Q1 alone, representing roughly one-third to one-half of its full-year hiring plan, exacerbating near-term margin pressure. At ¥1,563 per share, the stock trades at ~7.4x FY4/27 consensus EPS despite a history of ~100% five-year sales CAGR, 50%+ ROE, and strong cash generation. Concerns also include capital allocation decisions such as launching a leasing business and overseas expansion, while dividends have been withheld despite a large cash balance. The pitch argues the market is overreacting to what is likely a temporary margin issue.

BSD Analysis:
M&A Research Institute operates a differentiated, fully online brokerage model that structurally shortens transaction timelines through proprietary matching algorithms, supporting historically exceptional ROIC and scalability. Industry structure in Japanese SME M&A remains underpenetrated with long secular tailwinds from succession-driven deal flow, suggesting demand is not the limiting factor. The current earnings reset reflects execution timing rather than franchise degradation, as elevated deal backlog implies revenue recovery once hiring productivity normalizes. That said, rapid headcount expansion raises legitimate questions around marginal returns on labor and cultural dilution in a relationship-driven business. Capital allocation into adjacent businesses and overseas markets introduces risk, particularly if management strays from its core high-ROIC model. Valuation at ~7x forward earnings prices in a structurally lower growth profile and little operating leverage recovery. If conversion rates revert and hiring proves productive, earnings power could be materially understated, making the current drawdown an opportunity rather than a value trap.

Actual Post Content:
M&A Research $9552.T (approx. $750mm mcap) is trading limit down overnight on weak Q1 earnings. Sales are tepid while hiring is faster-than-planned, resulting in a 50% OP decline. At 1563 yen, it trades @ 7.4x FY4/27 consensus EPS. Aboslute cash cow 100% 5yr sales CAGR, 50+% ROE. 1/ We see the margin compression as temporary, as new hires should start contributing to higher conversion rates next FY. Deals in progress are at a record high growing to 1352 (+11.2% QoQ), yet closures only at 728. 2/ Hires were front-loaded in Q1. 43 hires have been made in Q1, representing 33%-54% of full-year target. Deal closures were down 1 contract y/y, while fees per deal fell from 74mn to 61mn, resulting in overall sales decline. Sales down, hiring up = OP down. 3/ A few capital allocation issues, like launching Souken Leasing, a leasing biz, albeit not quite sure if there's synergy or better margins. Overseas expansion also in progress, which might work. Dividends withheld, though now sitting on huge cashpile. * What makes M&A Souken special is it's a fully-online brokerage focusing on shorter times until M&A completion by leveragin in-house matching algorithms. This has resulted in 100% 5yr topline CAGR @ 50+% ROIC, though now rapidly slowing. Yet at 7x FY27 EPS, it now looks cheap.

URL: https://x.com/TeddyOkuyama/status/1884924298697355274

Pitch Summary:
Other negative contributors to the portfolio in the fourth quarter included Hypoport, a German financial services platform specializing in mortgage and insurance solutions. Hypoport, which has been a significant positive driver in the past, declined 41% during the quarter, returning to our average cost. Its performance appears to remain closely tied to interest rate sentiment, despite its business fundamentals being less sensitive to such changes. For 2024, we project 25% revenue growth with a 10% increase in profitability. This is expected to be followed by 15% revenue growth and a 35% rise in profitability in 2025.5 We took advantage of the recent sell-off to increase our position.

BSD Analysis:
Hypoport’s share price has become overly correlated with German rate expectations even though its underlying platforms enjoy structural tailwinds from digitisation and broker consolidation. The company runs asset-light marketplaces with high incremental margins, so sustained double-digit revenue growth should translate into outsized profit expansion as volumes recover. Near-term earnings will still be influenced by housing-market activity, but management has a strong record of investing through downturns to gain share when conditions normalise. Balance sheet conservatism and recurring fee income reduce solvency risk, allowing long-term investors to look through cyclical volatility. From a depressed valuation relative to its history and to global fintech peers, successful delivery on the growth pipeline could lead to a strong re-rating.

Pitch Summary:
Among the top five detractors for the fourth quarter were two holdings from the Consumer sector: Royal Unibrew and FeverTree. Royal Unibrew, a leading European beverage producer, declined 8%, returning to our historical cost basis. FeverTree, a premium mixer company known for its tonic waters, experienced an 18% drop, ending 2024 approximately 20% below our average cost for the investment.4 These performance levels are far from what we would consider impairments. Both companies operate within the everyday purchase category, which we believe is less economically sensitive than large-ticket discretionary spending. Importantly, we believe FeverTree and Royal Unibrew maintain strong balance sheets and have significant potential to restore margins to historical levels. This gives us confidence that, with patience, the investments we have in these companies will yield meaningful rewards over the long term. Since “a picture is worth a thousand words,” the chart below illustrates how both companies currently compare on a historical multiple of profitability. As evidenced above, both companies are currently trading at their lowest earnings multiples in a decade, based on both 2024 and projected 2025 earnings. This is despite delivering impressive revenue growth over the same period—20% annualized for FeverTree and 10% for Royal Unibrew. From our assessment, the primary driver of this valuation compression has been margin pressures, which remain a critical determinant of their future value creation. This dynamic was evident at the time of our initial investment and continues to hold true today. With margins improving by 30% at FeverTree and remaining stable for Royal Unibrew, both companies have performed in line with our expectations. We believe it is only a matter of time before their stock prices reflect their strong underlying fundamentals. 5

BSD Analysis:
Fever-Tree is a premium beverage brand with powerful global positioning whose equity story has been temporarily derailed by cost inflation and margin compression. The company continues to grow revenues at a double-digit pace, helped by international expansion and category leadership in premium mixers, but profitability has lagged as glass, logistics and input costs spiked. With pricing, product mix and cost efficiencies starting to repair margins, there is significant operating leverage to higher EBIT as volumes scale through existing distribution. The balance sheet is clean and reinvestment needs are modest, so a higher proportion of future cash flow can be directed to shareholders once the capex bulge passes. At depressed earnings multiples versus its own history and global staples peers, successful execution on margin normalisation could drive outsized equity returns.

Pitch Summary:
Plaid Inc. is positioned as a leader in Japan's marketing automation sector, with its product Karte driving significant client engagement. Despite a temporary slowdown in growth, the company has rebounded with a strong annual recurring revenue (ARR) growth rate exceeding 20%. Trading at a discount compared to peers, Plaid offers a compelling investment opportunity with potential upside from valuation re-rating and continued revenue growth.

BSD Analysis:
Plaid's valuation appears attractive, trading at 3.1x EV/TTM ARR compared to peers at 5x or higher. The company's strategic focus on high-value clients and improved customer success initiatives have bolstered its net revenue retention to 111.4%. With a small market cap of Y34bn, Plaid has been overlooked by institutional investors, presenting an opportunity for significant re-rating as it continues to grow. The company's direct sales strategy and consulting services enhance customer acquisition and retention, supporting its growth trajectory. Furthermore, the planned price increase for Karte services could provide additional revenue and profit growth, although its impact may be more pronounced in the fiscal year ending September 2026. Overall, Plaid's strategic initiatives and market position suggest a promising outlook for long-term investors.

Pitch Summary:
@NeuroStockDoc pitches ACOG as a tolerability-focused Alzheimer’s drug launch story centered on ZUNVEYL, a prodrug of galantamine designed to reduce GI and insomnia issues. The drug targets LTC settings where AD prevalence is extremely high and half of patients cannot tolerate existing meds. Survey data shows strong physician intent to prescribe, and the author sees rapid adoption and a path to break-even in three years. With a $2B LTC TAM versus a ~$100M market cap, the setup appears meaningfully asymmetric.

BSD Analysis:
ZUNVEYL occupies a strategically attractive niche by improving tolerability within a well-established AD drug class, reducing clinical, regulatory, and adoption risk relative to novel mechanisms. Industry structure in AD favors incremental improvements that expand the treatable population, particularly in institutional settings where adherence and side effects drive outcomes and reimbursement optics. LTC is an efficient beachhead: concentrated prescribers, aligned incentives, and high prevalence create favorable go-to-market economics for a small commercial organization. The key risk is commercial execution rather than efficacy, as differentiation is meaningful but not disruptive, placing pressure on pricing, access, and messaging. Longer-term optionality from Phase 4 data and alternative formulations could expand durability beyond the initial launch window. Valuation implies skepticism that modest differentiation can translate into scale, yet even limited penetration of the LTC subset would justify a materially higher equity value. If uptake mirrors stated prescriber intent, downside appears asymmetric relative to the current pre-revenue market cap.

Actual Post Content:
New brief thesis: $ACOG ZUNVEYL is an acetylcholinesterase inhibitor. These are standard of care for mild-mod Alzheimer (AD), but have lots of side effects (GI and insomnia). ZUNVEYL is prodrug of Galantamine which helps it avoid GI side effects b/c it goes to the liver first. Initial target is long term care (LTC) residents (e.g. nursing homes). ~70% residents have AD. 50% cant tolerate AD meds. LTC has quality metrics to hit. Both LTC and patients incentivized to use ZENVEYL due to efficacy and tolerability. Neurologists are likely to use ZUNVEYL. Why? it is quite similar to existing meds, but more tolerable. Its not a whole new unknown drug. Many patients likely to switch. So ZUNVEYL is differentiated enough from current drugs, but similar enough to make it easy to adopt. 88% of LTC Drs said likely to prescribe + LTC facilities have incentive to promote them. LTC = 36% of AD market ~ $2 billion TAM (just LTC). ACOG Current market cap = $101 M. Currently they are pre-revenue, but launching in March 2025. Sales force almost all hired. Projecting break even in 3 years. More coming: phase 4 study, sublingual formula. If they execute, I don’t see how this drug fails. Long $ACOG.

URL: https://x.com/neurostockdoc/status/1884785767307710504

Pitch Summary:
Huge insurance loss expected due to the fire; loss of capital; without additional insurance, the company can't pay out the claims; $2 bil of policy holder losses;

BSD Analysis:
Mercury General is a regional auto and property insurer. The short thesis stresses margin compression from elevated claims inflation, adverse underwriting cycles, and reliance on California auto markets where regulatory approval delays hinder rate adjustments. With high catastrophe exposure and limited diversification, Mercury faces structural disadvantages versus larger insurers.

Pitch Summary:
Natural Resource Partners presents a compelling investment opportunity due to its favorable risk/reward profile. The company is expected to significantly increase cash flow to unitholders in the next 12-24 months, driven by ongoing debt reduction efforts. Even if met coal prices remain stable, the units are attractive above $100. If the units re-rate to their historical distribution yield, they could potentially double in value.

BSD Analysis:
Natural Resource Partners has been strategically reducing its debt, which positions it well to enhance cash distributions to unitholders. The company's focus on maintaining a strong balance sheet and optimizing its portfolio could lead to a re-rating of its units. The coal market's supply/demand imbalance may pose challenges, but NRP's diversified mineral portfolio provides a buffer. The potential for a 15-20% yield is attractive, especially if the company continues to manage its financials prudently. Investors should monitor commodity price trends and the company's debt reduction progress as key indicators of future performance.